Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Claus BachertPeter W HellingsJoaquim MullolDaniel L HamilosPhilippe GevaertRobert M NaclerioVijay N JoishJingdong ChaoLeda P MannentNikhil AminAdeline AbbeChristine TaniouChunpeng FanGianluca PirozziNeil M H GrahamPuneet MahajanHeribert StaudingerAsif KhanPublished in: Allergy (2019)
In adults with CRSwNP refractory to treatment with INCS alone, the addition of dupilumab reduced disease severity, significantly improved HRQoL, and improved productivity.